DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

Information source: National Cancer Institute (NCI)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Brain and Central Nervous System Tumors; Cachexia; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unspecified Childhood Solid Tumor, Protocol Specific

Intervention: cyproheptadine hydrochloride (Drug); megestrol acetate (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: H. Lee Moffitt Cancer Center and Research Institute

Official(s) and/or principal investigator(s):
Jennifer L. Mayer, MD, Study Chair, Affiliation: H. Lee Moffitt Cancer Center and Research Institute

Summary

RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer.

PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and preventing weight loss in children with cachexia caused by cancer or cancer treatment.

Clinical Details

Official title: The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia

Study design: Supportive Care, Open Label

Primary outcome: Efficacy of study agents as measured by changes in weight at baseline, and 4 weeks after the beginning of study treatment

Secondary outcome: Effect of study agents on protein and fat levels as measured by pre-albumin and lipid profile at baseline, and 4 weeks after the beginning of study treatment

Detailed description: OBJECTIVES:

- Determine the efficacy of cyproheptadine in preventing further weight loss in children

with cancer or cancer treatment-related cachexia.

- Determine the efficacy of megestrol in preventing further weight loss in patients who

don't respond to cyproheptadine.

- Determine how these drugs affect body protein and fat levels in these patients.

OUTLINE: Patients receive oral cyproheptadine twice daily for 4 weeks in the absence of unacceptable weight loss or toxicity. Patients that present with weight loss after 4 weeks receive oral megestrol daily for 4 weeks in the absence of unacceptable weight loss or toxicity. Patients responding to either cyprohepatadine or megestrol may continue treatment at the discretion of the treating physician.

Patients are followed at 4 weeks.

PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.

Eligibility

Minimum age: 2 Years. Maximum age: 20 Years. Gender(s): Both.

Criteria:

DISEASE CHARACTERISTICS:

- Newly diagnosed or relapsed cancer of any type, including brain tumors

- Cachexia with weight loss presumed secondary to cancer or cancer-related treatment

defined as 1 or more of the following:

- Documented weight loss of at least 5%

- Drop in growth rate 2 or more percentile ranks on standard growth charts

- Weight for height less than the tenth percentile

- No hormone-sensitive tumors (i. e., meningiomas, breast cancer, ovarian cancer, or

endometrial cancer)

PATIENT CHARACTERISTICS:

Age

- 2 to 20

Performance status

- Not specified

Life expectancy

- At least 8 weeks

Hematopoietic

- Not specified

Hepatic

- Not specified

Renal

- Not specified

Cardiovascular

- No thromboembolic disease

- No congestive heart failure

- No recurrent or persistent hypertension (i. e., blood pressure values greater than 20%

above normal)

Other

- Not pregnant or nursing

- Fertile patients must use effective contraception

- No type I or II neurofibromatosis

- No glaucoma

- No chronic persistent asthma

- No gastrointestinal or genitourinary obstruction

- No peripheral edema

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- No more than 8 weeks since prior chemotherapy

Endocrine therapy

- No concurrent corticosteroids except intermittent steroid use (≤ 7 days in a 4 week

period)

Radiotherapy

- No more than 8 weeks since prior radiotherapy

Surgery

- No more than 8 weeks since prior surgery

- Concurrent tumor-debulking surgery, limb-sparing surgery, or amputation allowed

Other

- More than 3 weeks since prior cyproheptadine or megestrol

- More than 3 weeks since prior dronabinol or other appetite-stimulating medications

- More than 1 week since prior parenteral nutrition or tube feedings

- No more than 8 weeks since prior other anticancer therapy

- No other concurrent appetite-stimulating medications

- No concurrent parenteral nutrition or tube feedings

- No concurrent monoamine oxidase inhibitors (e. g., moclobemide, phenelzine, or

tranylcypromine)

- Concurrent active or palliative therapy allowed

Locations and Contacts

San Jorge Children's Hospital, Santurce 00912, Puerto Rico

CCOP - Bay Area Tumor Institute, Oakland, California 94609-3305, United States

Children's Hospital & Research Center Oakland, Oakland, California 94609, United States

Children's National Medical Center, Washington, District of Columbia 20010-2970, United States

All Children's Hospital, St. Petersburg, Florida 33701, United States

CCOP - Florida Pediatric, Tampa, Florida 33682-7757, United States

Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida 33407, United States

Nemours Children's Clinic, Jacksonville, Florida 32207, United States

Sacred Heart Cancer Center at Sacred Heart Hospital, Pensacola, Florida 32504, United States

St. Joseph's Children's Hospital of Tampa, Tampa, Florida 33677-4227, United States

University of Florida Shands Cancer Center, Gainesville, Florida 32610-0296, United States

MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia 30912-4000, United States

Cancer Research Center of Hawaii, Honolulu, Hawaii 96813, United States

Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas 66160-7357, United States

Children's Hospital of New Orleans, New Orleans, Louisiana 70118, United States

Floating Hospital for Children at Tufts - New England Medical Center, Boston, Massachusetts 02111, United States

CCOP - Beaumont, Royal Oak, Michigan 48073-6769, United States

DeVos Children's Hospital, Grand Rapids, Michigan 49503, United States

Van Elslander Cancer Center at St. John Hospital and Medical Center, Detroit, Michigan 48236, United States

Children's Hospitals and Clinics of Minnesota - Minneapolis, Saint Paul, Minnesota 55106-2049, United States

University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, United States

Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri 63110, United States

Tomorrows Children's Institute at Hackensack University Medical Center, Hackensack, New Jersey 07601, United States

Roswell Park Cancer Institute, Buffalo, New York 14263-0001, United States

SUNY Upstate Medical University Hospital, Syracuse, New York 13210, United States

Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina 28232-2861, United States

Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina 27157-1096, United States

Children's Hospital Medical Center of Akron, Akron, Ohio 44308-1062, United States

Children's Medical Center - Dayton, Dayton, Ohio 45404-1815, United States

Columbus Children's Hospital, Columbus, Ohio 43205-2696, United States

Tod Children's Hospital, Youngstown, Ohio 44501, United States

Legacy Emanuel Hospital and Health Center & Children's Hospital, Portland, Oregon 97227, United States

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213, United States

Hopital Sainte Justine, Montreal, Quebec H3T 1C5, Canada

Montreal Children's Hospital at McGill University Health Center, Montreal, Quebec H3G 1A4, Canada

CCOP - Scott and White Hospital, Temple, Texas 76508, United States

CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas 78207, United States

MBCCOP - South Texas Pediatrics, San Antonio, Texas 78229-3900, United States

Methodist Cancer Center at Methodist Specialty and Transplant Hospital, San Antonio, Texas 78229-3902, United States

Vermont Cancer Center at University of Vermont, Burlington, Vermont 05405-0110, United States

Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia 23298-0121, United States

Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington 98105-3916, United States

St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin 54307-9070, United States

Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: June 2003
Last updated: May 23, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008